Q4: For people with dementia with associated depression, do antidepressants when compared to placebo/comparator produce benefits/harm in the specified outcomes?
Q2: For people with dementia, does memantine, when compared to placebo/comparator, produce benefits/harm in the specified outcomes in non-specialist health settings?
Rapport du Directeur général
SOIXANTE-DIXIÈME ASSEMBLÉE MONDIALE DE LA SANTÉ A70/28 Point 15.2 de l’ordre du jour provisoire 3 avril 2017
Q6: Can dementia be diagnosed at first or second level care by non-specialist health care providers? What should be the assessment process for the diagnosis of dementia?
Q3: For behavioural and psychological symptoms in people with dementia, do following drugs, when compared to placebo/comparator, produce benefits/harm in the specified outcomes?
November 3, 2009https://doi.org/10.1371/journal.pmed.1000176
PLoS Med 6(11): e1000176. https://doi.org/10.1371/journal.pmed.1000176
Q8. Should Anti-Epileptic Drug (AED) treatment be started after first unprovoked seizure in non-specialist health settings?
Q 7: For adults and children with convulsive epilepsy, which standard antiepileptic drugs (phenobarbital, phenytoin, carbamazepine, valproic acid) when compared to placebo/a comparator produce benefits/harm in the specified outcomes?
This paper focuses on the Sustainable Development Goals related to poverty, economic growth, inequality, health, food production and the environment. It presents concrete examples of the underlying and complex aspects of antibiotic resistance and its impacts across different Sustainable Development ...Goals. The aim of this paper is to inform and stimulate discussions on how to further advance the implementation of 2030 Agenda for Sustainable Development, the Global Action Plan on Antimicrobial Resistance, National Action plans on Antimicrobial Resistance, as well as work within all sectors that affect and are affected by antibiotic resistance
more
Accessed: 10.03.2019
mhGAP Training Manual for the mhGAP Intervention Guide for mental, neurological and substance use disorders in non-specialized health settings – version 2.0 (for field testing)
Recommandations francaises pour la prise enc harge du chikungunya
Médecine e tmaladies infectieuses 45(2015)243–263
This report aims to improve the assessment of mental health needs in the Americas by providing an updated and nuanced picture of: (a) the disability resulting from mental, substance use, and specific neurological disorders, plus self-harm, alone and in combination with premature mortality; (b) the i...mbalance between mental health spending and its related disease burden; and (c) the inadequate allocation of the meager mental health spending by countries of the Region
more
El documento La carga de los trastornos mentales en la Región de las Américas, 2018 tiene como propósito mejorar la evaluación de las necesidades en materia de salud mental en la Región de las Américas al presentar un panorama actualizado y matizado de: a) la discapacidad debida a los trastorn...os mentales, por consumo de sustancias y trastornos neurológicos específicos, más la autoagresión (TMNS), tanto sola como en combinación con la mortalidad prematura; b) el desequilibrio entre el gasto en salud mental y la carga de enfermedad relacionada; y c) la asignación inadecuada de los exiguos gastos en salud mental por parte de los países de la Región
more
For the 24th consecutive year, PAHO has published the report Health Situation in the Americas: Core Indicators featuring the latest information on key indicators for the Region of the Americas. This 2018 edition includes data on the 82 core indicators for the countries, territories, and sub regions ...of the Americas, grouped into the following categories: demographic-socioeconomic, health status, risk factors, service coverage, and health systems. Information is also presented on 22 indicators of the Sustainable Development Goals (SDGs).
more
Guide de référence rapide à l’intention des autorités sanitaires et des soignants
Révisé en 2015
Int J Crit Illn Inj Sci. 2012 May-Aug; 2(2): 82–97.
doi: 10.4103/2229-5151.97273
PMCID: PMC3401822
PMID: 22837896
Cureus. 2015 Nov; 7(11): e372.
Published online 2015 Nov 3. doi: 10.7759/cureus.372
PMCID: PMC4671837
PMID: 26677422
Published: 5 January 2010 Received: 30 January 2009
BMC Neurology 2010, 10:1 doi:10.1186/1471-2377-10-1
This article is available from: http://www.biomedcentral.com/1471-2377/10/1
методические рекомендации на тему эпидемиологические исследования паркинсонизма,